Therapeutic drugs for targeting chloroquine resistance in malaria.
While the post-genomic era could lead into new targets for antimalarial drug development, herein few successful targets including medicinals involved in those processes are presented. Further, contribution of bioinorganic chemistry has also started to make its impact in the field of pharmaceuticals. Therefore, metal chelators, selected organometallics, and metalloantimalarials that would offer potential therapeutic drugs are also discussed. Finally, a brief summary on chloroquine-resistance mechanism(s) has been included.
Sharma
Vijay
V
Mallinckrodt Institute of Radiology, Washington University Medical School, St. Louis, MO 63110, USA. sharmav@mir.wustl.edu
D000818:Animals; D000962:Antimalarials / Q000737:chemistry* / Q000627:therapeutic use*; D002614:Chelating Agents / Q000737:chemistry / Q000627:therapeutic use; D002738:Chloroquine / Q000494:pharmacology* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D004351:Drug Resistance; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D010961:Plasmodium / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism
D000962:Antimalarials; D002614:Chelating Agents; D002738:Chloroquine